

Research Article

**Analysis of therapeutic effects of low dose unitrexate in
neuropathological disorders in Pakistan**

**Hammad Mehmood¹, Sana Tabassam²
and Bisma Fater Bakhsh²**

¹MO at D.H.Q Jehlum, Pakistan.

²WMO at D.H.Q Jehlum, Pakistan

Corresponding author: Dr Hammad Mehmood, MO at D.H.Q Jehlum, Pakistan.

Contact: 0092-333-5802332. **Email:**hammadmirza17@gmail.com

ABSTRACT

Introduction: There are many biochemical and inflammatory reactions which develop due to the effect of secondary spinal cord injury (SCI) are also called secondary cord damage creates the edema during acute stage. **Objectives of the study:** Based on all facts this study was designed to investigate the comparison of effects of low-dose unitrexate in neuropathological disorders in Pakistan. **Material and methods:** This experimental study was performed in Jehlum Hospital with the collaboration of CEMB. This study was done according to the ethical committee of university and hospitals and all the protocols were reviewed by the committee. A total of 100 patients were selected for study who was suffering from any neurological disorder and use these type of drugs. The study was further divided into further groups. **Results:** The variations between the mean values of MPO levels were significant according to the ANOVA and t-test. There were significant difference between control groups and treated groups. The data shows that the group of patients which was treated with both MTX and MP as a combine effect shows more close values to the control. But the separate effect shows somehow different values as compared to control. **Conclusion:** Low dose unitrexate is more effective as compared to methylprednisolone in neurological disorders.

Key words: Dose, Injury, Unitrexate

INTRODUCTION

There are many biochemical and inflammatory reactions which develop due to the effect of secondary spinal cord injury (SCI) are also called secondary cord damage creates the edema during acute stage¹. This effect includes the release of amino acid glutamate and aspartate, activation of arachidonic acid and activation of glial cells. Microglial cells produced superoxide and nitric oxide when they expose to oxidative stress. But according to modern treatment if we reduces the production of these cytokines by blocking these

inflammatory cells, it will reduces the secondary cord damage².

Now a days low dose unitrexate and methylprednisolone (MP) has been used for the treatment of some inflammatory diseases such as secondary spinal cord damage. Low dose MTX inhibits the proliferation of lymphocytes in any inflammatory response and also decreases the ability of leukocytes³. Exact mechanism of this drug is still unknown but according to some studies it increases the adenosine accumulation at

the inflammatory sites. Adenosine interacts with the receptors and decreases the inflammatory cells⁴.

MP is the first drug which is used for the treatment of spinal cord injury in animals and humans. This drug is considered to be the standard treatment method from whom which any other drugs will compare⁵. High dose of MP inhibits the lipid peroxidation. Current studies investigated that lipid peroxidation is a major provider to the progressive damage of tissue injury. MP protects the membrane against lipid peroxidation and it must be remembered that MP is a glucocorticosteroid drug and it also act through another mechanism in addition to lipid peroxidation⁶.

Objectives of the study

Based on all facts this study was designed to investigate the comparison of effects of low-dose unitrextate in neuropathological disorders in Pakistan.

MATERIAL AND METHODS

This experimental study was performed in Jehlum Hospital with the collaboration of CEMB. This study was done according to the ethical committee of university and hospitals and all the protocols were reviewed by the committee. A total of 100 patients were selected for study who was suffering from any neurological disorder and use these type of drugs. The study was further divided into further groups. The groups are as follows:

Group A: Control group

Group B: MTX- group (30mg/kg body weight)

Analysis of Specimen

For biochemical analysis of blood sample were processed with phosphate buffer saline using

homogenizer. Thiobarbituric acid reactive substances were measured according to the method of Mihara et al (9, 10). Myeloperoxidation (MPO) activity of the blood sample was measured according to the method of Suzuki et al¹².

Measurement of MPO activity

Blood homogenate was centrifuged at 3000rpm for 10 minutes and after that pallet was resuspended. Remove the pallet and again centrifuge at 3000rpm for 5 minutes. The resultant supernatant was separated and used for the measurement of MPO activity. Add 50mM phosphate buffer, 0.5% hexadecyltrimethyl ammonium bromide (HETAB), 1.6mM tetramethylbenzidine (TMB) and 2mM H₂O₂ and make the final volume of 1 ml. The reaction was started by the addition of H₂O₂ and absorbance was measured at 650 nm⁷.

Statistical analysis

Statistical analysis (one way-Anova Test and Post Hoc) was performed using the SPSS software program (18.0). All results were expressed as the mean ± standard deviation (SD). As P value <0.08 was considered to be statistically significant (14).

Results

Biochemical analysis

The variations between the mean values of MPO levels were significant according to the ANOVA and t-test. There were significant difference between control groups and treated groups. The data shows that the group of patients which was treated with both MTX and MP asa combine effect shows more close values to the control. But the separate effect shows somehow different values as compared to control (Table 1).

Table 1: Values of mean MPO and LPO in all groups of patients

Groups	Variables	Maximum	Minimum	Mean±SD
Control	LPO	35.33	30.35	30.00±7.32
	MPO	0.01	0.00	0.00±1.57
MTX	LPO	58.63	54.30	54.30±7.46
	MPO	14.53	11.36	12.50±0.84
MP	LPO	44.14	40.00	42.00±9.22

	MPO	5.32	4.85	3.25±5.20
MTX (High dose)+MP	LPO	35.00	33.00	32.25±11.68
	MPO	64.14	60.14	62.14±6.14
MTX+MP (High dose)	LPO	14.80	13.80	12.32±2.61
	MPO	38.00	36.33	35.32±0.64

DISCUSSION

There are many pharmacological agents which described or considered as a potentially strong therapeutic effects for SCI. Steroids are also accepted as a best possible option for the treatment of SCI. They have antioxidant and anti-inflammatory and may be favorable in a time- and dose-dependent manner⁸. They have also anti-edema activities. In our present study almost all groups show degenerative activities except control and combined treatment group. The histopathological grades show the inflammatory reactions in the specimen and it also shows the cell degeneration. These findings may explain the anti-inflammatory response of MTX and MD⁹.

Furthermore moderate inflammatory reaction caused by neutrophils was observed in the MP group, and severe inflammatory reaction developed due to macrophages was observed in the specimens of the MTX group¹⁰. This may mean that MP could not block the neutrophil infiltration into the damaged tissue, and low-dose MTX may enhance the macrophage or histiocytic infiltration into the injured neural tissue in the sub-acute stage of SCI¹¹.

Neutrophils and macrophages are the best source of inflammatory reactions and free radicals in any tissue. Moreover, ischemia induced by SCI faces tissue energy demands and active ion channel functions, and then it may force the neurons to switch from aerobic to anaerobic metabolism. This oxidative stress subsequent SCI may also produce free radicals, which may initiate the LPO activity in the damaged neural tissue¹².

These results also indicated that low dose MTX and MD also contribute in the formation of free radicals and decrease the oxidative stress¹³. When the neutrophils and other phagocytes reach the injured spinal cord tissue, they produce hypochlorite, a strong oxidant synthesized by the

enzyme MPO. MPO is the enzyme which is present in the granules of the neutrophils cells. MPO activity is associated with the total number of neutrophils and their activations¹⁴⁻¹⁵.

CONCLUSION

Low dose unitrexate is more effective as compared to methylprednisolone in secondary spinal cord injury

REFERENCES

1. Bao F, Chen Y, Dekaban GA, Weaver LC. Early anti-inflammatory treatment reduces lipid peroxidation and protein nitration after spinal cord injury in rats. *J Neurochem* 2004; 88:1335-44.
2. Kaynar MY, Hanci M, Kafadar A, Gümüştaş K, Belce A, Ciplak N. The effect of duration of compression on lipid peroxidation after experimental spinal cord injury. *Neurosurg Rev* 1998; 21:117-20.
3. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of unitrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. *J Clin Invest* 1993; 92:2675-82.
4. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. *Ann Rheum Dis* 2009; 68:1105-12.
5. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. *Arthritis Res* 2002; 4:266-73.
6. Brcken MB, Shepard MJ, Hellenbrand KG, methylprednisolone and neurological

- function 1 year after spinal cord injury. *J Neurosurg* 1985; 63:704-13.
7. Faden AI, Jacobs TP, Patrick DH, Smith MT. Megadose corticosteroid therapy following experimental traumatic spinal injury. *J Neurosurg* 1984; 60: 712-7.
 8. Hall ED. The neuroprotective pharmacology of methylprednisolone. *J Neurosurg* 1992; 76: 13-22.
 9. Means ED, Anderson DK, Waetrs TR, Kalaf L. Effect of methylprednisolone in compression trauma to the feline spinal cord. *J Neurosurg* 1981; 55: 200-8.
 10. Braughler JM, Hall ED. Effects of multi-dose methylprednisolone sodium succinate administration on injured cat spinal cord neurofilament degradation and energy metabolism. *J Neurosurg* 1984; 61: 290-5.
 11. Rivlin AS, Tator CH. Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. *Surg Neurol* 1978; 10:38-43.
 12. Demirpençe E, Köksoy C, Kuzu A, Kılınç K. A spectrophotometric assay for tissue associated myeloperoxidase activity and its application to intestinal ischemia-reperfusion. *Turk J Med Sci* 1997; 27:197-200.
 13. Suzuki K, Ota H, Sasagawa S, Sakatani T, Fujikura T. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. *Anal Biochem* 1983;132:345-52.
 14. Nie NH, Hull CH, Jenkins JG. SPSS: statistical package for social science. New York: McGraw Hill Inc.; 1975.
 15. Leskovar A, Moriarty LJ, Turek JJ, Schoenlein IA, BorgensRB. The macrophage in acute neural injury: changes in cellnumbers over time and levels of cytokine production in mammalian central and peripheral nervous systems. *J ExpBiol* 2000; 203:1783-95.